- Home
- BOW vs ARQT Comparison
BOW vs ARQT Comparison
Compare BOW & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- ARQT
- Stock Information
- Founded
- BOW 2020
- ARQT 2016
- Country
- BOW United States
- ARQT United States
- Employees
- BOW N/A
- ARQT N/A
- Industry
- BOW Property-Casualty Insurers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- ARQT Health Care
- Exchange
- BOW Nasdaq
- ARQT Nasdaq
- Market Cap
- BOW 1.2B
- ARQT 1.7B
- IPO Year
- BOW 2024
- ARQT 2020
- Fundamental
- Price
- BOW $33.30
- ARQT $15.25
- Analyst Decision
- BOW Buy
- ARQT Strong Buy
- Analyst Count
- BOW 6
- ARQT 6
- Target Price
- BOW $39.67
- ARQT $18.80
- AVG Volume (30 Days)
- BOW 219.2K
- ARQT 1.9M
- Earning Date
- BOW 08-05-2025
- ARQT 08-13-2025
- Dividend Yield
- BOW N/A
- ARQT N/A
- EPS Growth
- BOW 18.99
- ARQT N/A
- EPS
- BOW 1.33
- ARQT N/A
- Revenue
- BOW $457,704,000.00
- ARQT $212,819,000.00
- Revenue This Year
- BOW $22.94
- ARQT $61.01
- Revenue Next Year
- BOW $20.42
- ARQT $37.95
- P/E Ratio
- BOW $25.05
- ARQT N/A
- Revenue Growth
- BOW 45.29
- ARQT 100.03
- 52 Week Low
- BOW $24.80
- ARQT $7.86
- 52 Week High
- BOW $42.29
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- ARQT 65.06
- Support Level
- BOW N/A
- ARQT $13.06
- Resistance Level
- BOW N/A
- ARQT $15.36
- Average True Range (ATR)
- BOW 0.00
- ARQT 0.65
- MACD
- BOW 0.00
- ARQT 0.22
- Stochastic Oscillator
- BOW 0.00
- ARQT 91.54
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.